| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CTP |
| Uniprot No | P17812 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-591aa |
| 氨基酸序列 | MKYILVTGGVISGIGKGIIASSVGTILKSCGLHVTSIKIDPYINIDAGTF SPYEHGEVFVLDDGGEVDLDLGNYERFLDIRLTKDNNLTTGKIYQYVINK ERKGDYLGKTVQVVPHITDAIQEWVMRQALIPVDEDGLEPQVCVIELGGT VGDIESMPFIEAFRQFQFKVKRENFCNIHVSLVPQPSSTGEQKTKPTQNS VRELRGLGLSPDLVVCRCSNPLDTSVKEKISMFCHVEPEQVICVHDVSSI YRVPLLLEEQGVVDYFLRRLDLPIERQPRKMLMKWKEMADRYDRLLETCS IALVGKYTKFSDSYASVIKALEHSALAINHKLEIKYIDSADLEPITSQEE PVRYHEAWQKLCSAHGVLVPGGFGVRGTEGKIQAIAWARNQKKPFLGVCL GMQLAVVEFSRNVLGWQDANSTEFDPTTSHPVVVDMPEHNPGQMGGTMRL GKRRTLFQTKNSVMRKLYGDADYLEERHRHRFEVNPVWKKCLEEQGLKFV GQDVEGERMEIVELEDHPFFVGVQYHPEFLSRPIKPSPPYFGLLLASVGR LSHYLQKGCRLSPRDTYSDRIGSSSPDSEITELKFPSINHD |
| 预测分子量 | 91 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CTP重组蛋白的3篇参考文献概览，供您参考：
---
1. **文献名称**: *Enhancing the stability of recombinant proteins by fusion with C-terminal peptide (CTP) of human chorionic gonadotropin*
**作者**: Smith A, et al.
**摘要**: 本研究探讨了将人绒毛膜促性腺激素(hCG)的CTP结构域融合至治疗性蛋白(如促红细胞生成素)的C端，通过延长其血清半衰期和增强蛋白稳定性，显著提高了重组蛋白的药效。
2. **文献名称**: *CTP fusion technology for improved pharmacokinetics of therapeutic proteins: a case study with FSH*
**作者**: Jones R, et al.
**摘要**: 文章分析了CTP融合技术在卵泡刺激素(FSH)中的应用，证明CTP修饰可减少肾脏清除率并提高蛋白溶解度，为长效激素制剂的开发提供了新策略。
3. **文献名称**: *Optimization of CTP-fused protein expression in CHO cells for industrial production*
**作者**: Lee H, et al.
**摘要**: 该研究优化了中国仓鼠卵巢(CHO)细胞中CTP融合蛋白的表达条件，通过载体设计和培养参数调整，实现了重组蛋白产量提升50%，为大规模生产提供了技术基础。
---
**备注**：以上文献为示例性质，实际引用时建议通过PubMed或Google Scholar以关键词“CTP fusion protein”、“recombinant protein stability”等检索最新研究。若需具体文献，可提供更多研究背景进一步筛选。
CTP (C-terminal peptide) recombinant proteins are engineered biologics designed to enhance the therapeutic efficacy and pharmacokinetic properties of naturally occurring proteins. The concept originates from the discovery that certain peptide sequences, particularly those derived from the carboxyl terminus of human chorionic gonadotropin (hCG), can prolong the half-life of proteins in circulation. This is achieved by reducing renal clearance and delaying enzymatic degradation, thereby improving bioavailability. The CTP sequence, a 28-amino acid motif, has been extensively studied for its ability to extend protein stability without significantly altering biological activity.
The development of CTP technology emerged as an alternative to traditional half-life extension methods like PEGylation or Fc fusion, which can sometimes trigger immune responses or interfere with target binding. By contrast, CTP fusion maintains a more natural protein structure while providing comparable or superior pharmacokinetic benefits. This approach gained traction in the 2000s with successful preclinical studies demonstrating enhanced duration of action for hormones like erythropoietin and follicle-stimulating hormone (FSH).
Pharmaceutical applications focus primarily on chronic conditions requiring frequent dosing. Notable examples include Elranatamab (a bispecific antibody with CTP modification) and FSH-CTP (corifollitropin alfa), an FDA-approved fertility treatment showing week-long efficacy versus daily injections of native FSH. Current research explores CTP's potential in vaccines, enzyme replacement therapies, and cytokine modulators. Challenges remain in optimizing peptide length, minimizing immunogenicity risks, and balancing extended half-life with proper tissue penetration. As biologic therapies continue to dominate pharmaceutical pipelines, CTP recombinant proteins represent a strategic advancement in precision drug design and patient compliance optimization.
×
